The recent pandemic provides context for the global need to increase manufacturing readiness of biopharmaceuticals and vaccines. New strategies towards continuous and distributed manufacturing will be required to meet the envisioned benefits of new therapies on a global scale with equity. Proof of concept for systems that could achieve capacity and speed and quality and configurability together will be discussed.
J. Christopher Love is the Raymond A. (1921) and Helen E. St. Laurent Professor of Chemical Engineering and member of the Koch Institute for Integrative Cancer Research at MIT. In addition, he is an associate member at the Eli and Edythe L. Broad Institute, and at the Ragon Institute of MGH, MIT, and Harvard. Prof. Love received his Ph.D. in 2004 in physical chemistry at Harvard University. He extended his research into immunology at Harvard Medical School from 2004-2005, and at the Immune Disease Institute from 2005-2007. His research centers on using simple microsystems to monitor cells from clinical samples in chronic human diseases, and on developing new approaches to manufacturing biologic drugs and vaccines efficiently and affordably. Prof. Love was named a Dana Scholar for Human Immunology and a Keck Distinguished Young Scholar in Medical Research in 2009, one of Popular Science’s Brilliant 10 in 2010, and also a Camille Dreyfus Teacher-Scholar. At MIT, he is the Director of the Alternative Host Consortium, a unique MIT-Industry partnership advancing new manufacturing hosts for biopharmaceuticals and vaccines. He previously served as a Distinguished Engineer in Residence at Biogen (2015-2016), and also consults for several biotechnology and biopharmaceutical companies, including three current start-ups based on technologies from his lab at MIT (Honeycomb, OneCyte, and Sunflower).